Press Releases

Date Title and Summary Additional Formats
Toggle Summary Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 10, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of data from the first patients in the
View HTML
Toggle Summary Xencor Reports Third Quarter 2022 Financial Results
-- XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study -- -- Management to host conference call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 7, 2022-- Xencor, Inc.
View HTML
Toggle Summary Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
-- Durable, dose-dependent and selective expansion of CD25 bright Tregs, reaching a 117-fold increase over baseline at the highest dose -- -- Single dose of XmAb564 well-tolerated with no reported serious adverse events -- -- First patient dosed in Phase 1b, multiple-ascending dose study in
View HTML
Toggle Summary Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 3, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that clinical data from expansion cohorts in its Phase 1
View HTML
Toggle Summary Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 31, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release third quarter 2022 financial results after
View HTML
Toggle Summary Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
MONROVIA, Calif. --(BUSINESS WIRE)--Oct. 5, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced seven poster presentations at the 37th Annual Meeting of the
View HTML
Toggle Summary Xencor Appoints Nancy Valente, M.D., to Board of Directors
MONROVIA, Calif. --(BUSINESS WIRE)--Sep. 9, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the appointment of Nancy Valente , M.D., to its board of
View HTML
Toggle Summary Xencor Reports Second Quarter 2022 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Aug. 3, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported
View HTML
Toggle Summary Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
IRVING, Texas and MONROVIA, Calif. , Aug. 2, 2022 /PRNewswire/ --  Caris Life Sciences ® (Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize health care, and Xencor , Inc. (NASDAQ: XNCR), a clinical-stage
View HTML
Toggle Summary Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
MONROVIA, Calif. --(BUSINESS WIRE)--Jul. 27, 2022-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will release second quarter 2022 financial results after
View HTML